Several new treatment options for patients with breast cancer have emerged over the last few years, including more oral ...

University of Kentucky Markey Cancer Center researchers have discovered a promising new way to combat therapy-resistant ...

The University of Iowa study is analyzing the period between breast cancer diagnosis and treatment, when many patients feel ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.DN-d7ZPu.js ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

With Hologic, Inc. HOLX gearing up to release its fiscal 2025 first-quarter financial results on Feb. 5 after the market ...

Dewpoint Therapeutics’ second development candidate, DPTX3496 is an oral, small molecule acting via a novel condensate-modulating mechanism of ...

Triple negative breast cancer wreaks a particularly heavy toll in certain regions and populations, with stark differences in both incidence and survival rates ...

Breast cancer is more common after menopause than many realise, and understanding the risks, treatment options, and ...

A seasoned global health specialist has called for innovative and robust funding streams to escalate the treatment of cancer in Zambia.

The Phase III trial saw a clinically meaningful benefit in overall survival with a combination of Itovebi alongside Ibrance ...

The NHS, as well as experts in the field, have pointed out some red flags symptoms of prostate cancer that you should never ...